×
About 768 results

ALLMedicine™ Nail Psoriasis Center

Research & Reviews  215 results

Topical calcipotriol combined with urea 20% versus intralesional injection of triamcino...
https://doi.org/10.1111/dth.15660
Dermatologic Therapy; Abdelmeniem IM, Eryan IME et. al.

Jun 23rd, 2022 - There is no consistently effective treatment for psoriatic nails. Topical and intralesional modalities have been recently investigated and showed promising efficacy and safety. To compare the efficacy and safety of intralesional injection of 5-flu...

Fractional CO2 Laser Versus Pulsed Dye Laser in Nail Psoriasis
https://clinicaltrials.gov/ct2/show/NCT05415839

Jun 13th, 2022 - Study Design: Randomized Clinical Trial Inclusion criteria: All patients with bilateral nail psoriasis. Age: Above 18 Sex: both sexes Exclusion criteria: Cases who received treatment (systemic or topical) in the last 3 months before inclusion. Pat...

Hair and Nail Conditions: Nail Conditions.
https://www.ncbi.nlm.nih.gov/pubmed/35679470
FP Essentials; Mervak JE

Jun 10th, 2022 - A thorough understanding of nail anatomy can help physicians identify the causes of nail conditions. Observation of changes to the nail can help establish a diagnosis. Patient evaluation should include a physical examination, dermoscopy, and, in s...

Real-world evidence from the non-interventional, prospective, German multicentre PERSIS...
https://doi.org/10.1111/jdv.18218
Journal of the European Academy of Dermatology and Venere... Gerdes S, Asadullah K et. al.

May 16th, 2022 - PERSIST was a prospective, non-interventional, long-term, German multicentre study of patients with moderate-to-severe psoriasis receiving guselkumab, an approved monoclonal antibody that binds to the p19 subunit of interleukin (IL)-23, in a real-...

Factors Affecting Onychomycosis in Patients with Psoriasis.
https://doi.org/10.1111/dth.15513
Dermatologic Therapy; Yuksel Bozdemir N, Inan Yuksel E et. al.

Apr 16th, 2022 - Prevalence of onychomycosis increases in patients with psoriasis and that psoriasis predisposes to onychomycosis. It was aimed to determine the frequency of onychomycosis and responsible pathogens in patients with psoriasis, to reveal their differ...

see more →

Guidelines  1 results

Treatment of nail psoriasis: best practice recommendations from the Medical Board of th...
https://doi.org/10.1001/jamadermatol.2014.2983
JAMA Dermatology; Crowley JJ, Weinberg JM et. al.

Dec 5th, 2014 - Nail psoriasis can be difficult to treat and has a significant effect on quality of life. Relatively few controlled trials evaluating treatments for nail psoriasis have been published. There is an unmet need for treatment recommendations to guide ...

see more →

Clinicaltrials.gov  32 results

Fractional CO2 Laser Versus Pulsed Dye Laser in Nail Psoriasis
https://clinicaltrials.gov/ct2/show/NCT05415839

Jun 13th, 2022 - Study Design: Randomized Clinical Trial Inclusion criteria: All patients with bilateral nail psoriasis. Age: Above 18 Sex: both sexes Exclusion criteria: Cases who received treatment (systemic or topical) in the last 3 months before inclusion. Pat...

An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Deucravacitinib for the Treatment of Nail Psoriasis
https://clinicaltrials.gov/ct2/show/NCT05124080

Mar 11th, 2022 - . An open label proof of concept study will be conducted to assess the efficacy and safety of deucravactinib for treatment of nail psoriasis. Twenty adult patients with nail psorasis and skin disease qualifying for a systemic agent per investigato...

Assessing the Efficacy of Image-guided Laser-assisted Enstilar® Delivery for Treatment of Psoriatic Nails
https://clinicaltrials.gov/ct2/show/NCT04580537

Mar 2nd, 2022 - The trial is conducted to investigate the clinical efficacy of a combination product containing calcipotriol and betamethasone formulated as an aerosol foam (Enstilar ©) for the treatment of nail psoriasis in conjunction with physical pre-treatmen...

Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis
https://clinicaltrials.gov/ct2/show/NCT03897075

Feb 24th, 2022 - Phase 3b study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Nail Psoriasis

Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV)
https://clinicaltrials.gov/ct2/show/NCT04535999

Feb 14th, 2022 - This study will be an open label study of secukinumab for the treatment of nail psoriasis. Secukinumab is an FDA-approved treatment for psoriasis. This is a single arm trial - all patients will receive the study drug. We will examine time to respo...

see more →

News  56 results

Risankizumab Effective Against Refractory Psoriatic Arthritis
https://www.medscape.com/viewarticle/966708

Jan 18th, 2022 - NEW YORK (Reuters Health) - Risankizumab, an inhibitor of interleukin 23, provides some relief for patients with active psoriatic arthritis (PsA) whose symptoms have responded poorly to standard treatments, according to 24-week results of a phase-...

TNF-α inhibitor remains a promising therapy for nail psoriasis and concomitant PsA
https://www.mdedge.com/dermatology/article/249253/psoriatic-arthritis/tnf-inhibitor-remains-promising-therapy-nail

Dec 1st, 2021 - Key clinical point: Tumor necrosis factor (TNF)- α inhibitors effectively improved skin, nail, and joint symptoms and quality of life (QoL) in patients with nail psoriasis and concomitant psoriatic arthritis (PsA). Major finding: During the first.

Guselkumab Boosts Response in Resistant Psoriatic Arthritis
https://www.medscape.com/viewarticle/963861

Dec 1st, 2021 - NEW YORK (Reuters Health) - In patients with psoriatic arthritis (PsA) who are resistant to tumor necrosis factor inhibitors (TNFi), guselkumab was more effective than placebo in a phase IIIb trial. "Guselkumab is a relatively new treatment and is...

Risankizumab outperforms placebo at 6 months for psoriatic arthritis
https://www.mdedge.com/rheumatology/article/248387/psoriatic-arthritis/risankizumab-outperforms-placebo-6-months-psoriatic
Tara Haelle

Nov 8th, 2021 - Patients with psoriatic arthritis (PsA) showed more improvement in symptoms at 6 months with risankizumab (Skyrizi) than with placebo in combined phase 3, randomized, controlled trials, according to data presented at the virtual annual meeting of.

Risankizumab Outperforms Placebo at 6 Months for Psoriatic Arthritis
https://www.medscape.com/viewarticle/962500

Nov 8th, 2021 - Patients with psoriatic arthritis (PsA) showed more improvement in symptoms at 6 months with risankizumab (Skyrizi) than with placebo in combined phase 3, randomized, controlled trials, according to data presented at the virtual annual meeting of ...

see more →

Patient Education  3 results see all →